Stockreport

FDA Accepts Application for Genentech’s Faricimab for the Treatment of Wet Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME)

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF – Across four Phase III studies, approximately half of patients receiving faricimab could extend treatment time to every four months – the first time this level of durab [Read more]